Thymic Stromal Lymphopoietin Variation, Filaggrin Loss of Function, and the Persistence of Atopic Dermatitis | Allergy and Clinical Immunology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
1.
Leung  DY, Bieber  T.  Atopic dermatitis.  Lancet. 2003;361(9352):151-160.PubMedGoogle ScholarCrossref
2.
Abramovits  W.  Atopic dermatitis.  J Am Acad Dermatol. 2005;53(1)(suppl 1):S86-S93.PubMedGoogle ScholarCrossref
3.
Kabashima  K.  New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity.  J Dermatol Sci. 2013;70(1):3-11.PubMedGoogle ScholarCrossref
4.
Brown  SJ, McLean  WH.  One remarkable molecule: filaggrin.  J Invest Dermatol. 2012;132(3, pt 2):751-762.PubMedGoogle ScholarCrossref
5.
Smith  FJ, Irvine  AD, Terron-Kwiatkowski  A,  et al.  Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris.  Nat Genet. 2006;38(3):337-342.PubMedGoogle ScholarCrossref
6.
Irvine  AD, McLean  WH, Leung  DY.  Filaggrin mutations associated with skin and allergic diseases.  N Engl J Med. 2011;365(14):1315-1327.PubMedGoogle ScholarCrossref
7.
Fallon  PG, Sasaki  T, Sandilands  A,  et al.  A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming.  Nat Genet. 2009;41(5):602-608.PubMedGoogle ScholarCrossref
8.
Barnes  KC.  An update on the genetics of atopic dermatitis: scratching the surface in 2009.  J Allergy Clin Immunol. 2010;125(1):16-31, e1-e11. doi:10.1016/j.jaci.2009.11.008.PubMedGoogle ScholarCrossref
9.
Gao  PS, Rafaels  NM, Mu  D,  et al.  Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum.  J Allergy Clin Immunol. 2010;125(6):1403-1407, e4. doi:10.1016/j.jaci.2010.03.016.PubMedGoogle ScholarCrossref
10.
Demehri  S, Morimoto  M, Holtzman  MJ, Kopan  R.  Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma.  PLoS Biol. 2009;7(5):e1000067. doi:10.1371/journal.pbio.100006.PubMedGoogle ScholarCrossref
11.
Esnault  S, Rosenthal  LA, Wang  DS, Malter  JS.  Thymic stromal lymphopoietin (TSLP) as a bridge between infection and atopy.  Int J Clin Exp Pathol. 2008;1(4):325-330.PubMedGoogle Scholar
12.
Sherrill  JD, Gao  PS, Stucke  EM,  et al.  Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis.  J Allergy Clin Immunol. 2010;126(1):160-165, e3. doi:10.1016/j.jaci.2010.04.037. PubMedGoogle ScholarCrossref
13.
Li  M, Hener  P, Zhang  Z, Ganti  KP, Metzger  D, Chambon  P.  Induction of thymic stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin.  J Invest Dermatol. 2009;129(2):498-502.PubMedGoogle ScholarCrossref
14.
Soumelis  V, Reche  PA, Kanzler  H,  et al.  Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP.  Nat Immunol. 2002;3(7):673-680.PubMedGoogle Scholar
15.
Beck  LA, Boguniewicz  M, Hata  T,  et al.  Phenotype of atopic dermatitis subjects with a history of eczema herpecticum.  J Allergy Clin Immunol. 2009;124(2):260-269.PubMedGoogle ScholarCrossref
16.
Margolis  DJ, Apter  AJ, Gupta  J,  et al.  The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort.  J Allergy Clin Immunol. 2012;130(4):912-917.PubMedGoogle ScholarCrossref
17.
Sandilands  A, Terron-Kwiatkowski  A, Hull  PR,  et al.  Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema.  Nat Genet. 2007;39(5):650-654.PubMedGoogle ScholarCrossref
18.
Pritchard  JK, Stephens  M, Rosenberg  NA, Donnelly  P.  Association mapping in structured populations.  Am J Hum Genet. 2000;67(1):170-181.PubMedGoogle ScholarCrossref
19.
Reiner  AP, Carlson  CS, Ziv  E, Iribarren  C, Jaquish  CE, Nickerson  DA.  Genetic ancestry, population sub-structure, and cardiovascular disease–related traits among African-American participants in the CARDIA Study.  Hum Genet. 2007;121(5):565-575.PubMedGoogle ScholarCrossref
20.
Stefflova  K, Dulik  MC, Barnholtz-Sloan  JS, Pai  AA, Walker  AH, Rebbeck  TR.  Dissecting the within-Africa ancestry of populations of African descent in the Americas.  PLoS One. 2011;6(1):e14495. doi:10.1371/journal.pone.0014495.PubMedGoogle ScholarCrossref
21.
Rabe-Hesketh S, Skrondal A, Pickles A. GLLAMM Manual. October 2004. UC Berkeley Division of Biostatistics Working Paper Series; working paper 160. http://biostats.bepress.com/ucbbiostat/paper160. Accessed November 21, 2013.
22.
Rabe-Hesketh  S, Skrondal  A, Pickles  A.  Reliable estimation of generalized linear mixed models using adaptive quadrature.  Stata J. 2002;2(1):1-21.Google Scholar
23.
Bender  R, Lange  S.  Adjusting for multiple testing—when and how?  J Clin Epidemiol. 2001;54(4):343-349.PubMedGoogle ScholarCrossref
24.
Bouaziz  M, Ambroise  C, Guedj  M.  Accounting for population stratification in practice: a comparison of the main strategies dedicated to genome-wide association studies.  PLoS One. 2011;6(12):e28845. doi:10.1371/journal.pone.0028845. PubMedGoogle ScholarCrossref
25.
Willer  C, Li  Y, Avecasis  G.  METAL: fast and efficient meta-analysis of genome-wide association scans.  Bioinformatics. 2010;26(17):2190-2191.PubMedGoogle ScholarCrossref
26.
Margolis  DJ, Papadopoulos  M, Apter  AJ, McLean  WH, Mitra  N, Rebbeck  TR.  Obtaining DNA in the mail from a national sample of children with a chronic non-fatal illness.  J Invest Dermatol. 2011;131(8):1765-1767.PubMedGoogle ScholarCrossref
27.
Lee  KH, Cho  KA, Kim  JY,  et al.  Filaggrin knockdown and Toll-like receptor 3 (TLR3) stimulation enhanced the production of thymic stromal lymphopoietin (TSLP) from epidermal layers.  Exp Derm. 2011;20(2):149-151.PubMedGoogle ScholarCrossref
28.
Boguniewicz  M, Leung  DY.  Atopic dermatitis: a disease of altered skin barrier and immune dysregulation.  Immunol Rev. 2011;242(1):233-246.PubMedGoogle ScholarCrossref
29.
Kapoor  R, Hoffstad  O, Bilker  W, Margolis  DJ.  The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.  Pediatr Dermatol. 2009;26(6):682-687.PubMedGoogle ScholarCrossref
30.
Marenholz  I, Rivera  VA, Esparza-Gordillo  J,  et al.  Association screening in the Epidermal Differentiation Complex (EDC) identifies an SPRR3 repeat number variant as a risk factor for eczema.  J Invest Dermatol. 2011;131(8):1644-1649.PubMedGoogle ScholarCrossref
31.
Wu  Z, Hansmann  B, Meyer-Hoffert  U, Gläser  R, Schröder  JM.  Molecular identification and expression analysis of filaggrin-2, a member of the S100 fused-type protein family.  PLoS One. 2009;4(4):e5227. doi:10.1371/journal.pone.0005227. PubMedGoogle ScholarCrossref
32.
Pellerin  L, Henry  J, Hsu  CY,  et al.  Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin.  J Allergy Clin Immunol. 2013;131(4):1094-1102.PubMedGoogle ScholarCrossref
Original Investigation
March 2014

Thymic Stromal Lymphopoietin Variation, Filaggrin Loss of Function, and the Persistence of Atopic Dermatitis

Author Affiliations
  • 1Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 2Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 3Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia
JAMA Dermatol. 2014;150(3):254-259. doi:10.1001/jamadermatol.2013.7954
Abstract

Importance  Atopic dermatitis (AD) is a common chronic illness of childhood.

Objective  To evaluate the association between thymic stromal lymphopoietin (TSLP) variation and the persistence of skin symptoms of AD.

Design, Setting, and Participants  A prospective cohort study was conducted in the general community. Participants included 796 children enrolled in the Pediatric Eczema Elective Registry.

Exposure  Evaluation of TSLP variation.

Main Outcomes and Measures  Self-reported outcome of whether a child’s skin had no symptoms of AD and required no medications for 6 months at 6-month intervals.

Results  We evaluated 14 variants of TSLP. The variant rs1898671 was significantly associated with the outcome in white children (P = .01). As measured by overlapping CIs, similar odds ratios (ORs) were noted among whites (OR, 1.72; 95% CI, 1.11-2.66) and African Americans (1.33; 0.52-3.45). Further within the subcohort of individuals with a filaggrin protein (FLG) loss-of-function mutation, those with TSLP variation were more likely to have less-persistent disease (OR, 4.92; 95% CI, 2.04-11.86).

Conclusions and Relevance  The TSLP variation is associated with less persistent AD. Therefore, TSLP may be a potential therapeutic target for the treatment of AD, especially in individuals with diminished barrier function due to FLG mutations. This is an attractive hypothesis that can be tested in clinical trials.

×